Deutsche Bank’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.3M | Buy |
266,584
+139,115
| +109% | +$4.87M | ﹤0.01% | 1049 |
|
|
2026
Q1 | $4.91M | Buy |
127,469
+18,341
| +17% | +$677K | ﹤0.01% | 1302 |
|
|
2025
Q4 | $3.88M | Buy |
109,128
+13,001
| +14% | +$365K | ﹤0.01% | 1433 |
|
|
2025
Q3 | $1.38M | Buy |
96,127
+38,397
| +67% | +$455K | ﹤0.01% | 1985 |
|
|
2025
Q2 | $415K | Sell |
57,730
-13,167
| -19% | -$73K | ﹤0.01% | 2547 |
|
|
2025
Q1 | $425K | Sell |
70,897
-8,368
| -11% | -$65.6K | ﹤0.01% | 2567 |
|
|
2024
Q4 | $618K | Sell |
79,265
-83,593
| -51% | -$833K | ﹤0.01% | 2501 |
|
|
2024
Q3 | $1.76M | Sell |
162,858
-75,582
| -32% | -$736K | ﹤0.01% | 1834 |
|
|
2024
Q2 | $2.01M | Sell |
238,440
-486
| -0.2% | -$3.69K | ﹤0.01% | 1632 |
|
|
2024
Q1 | $1.61M | Buy |
238,926
+201,491
| +538% | +$1.25M | ﹤0.01% | 1770 |
|
|
2023
Q4 | $220K | Sell |
37,435
-599
| -2% | -$4.59K | ﹤0.01% | 2829 |
|
|
2023
Q3 | $371K | Buy |
38,034
+9,106
| +31% | +$108K | ﹤0.01% | 2361 |
|
|
2023
Q2 | $343K | Sell |
28,928
-14,971
| -34% | -$172K | ﹤0.01% | 2575 |
|
|
2023
Q1 | $474K | Buy |
43,899
+8,628
| +24% | +$110K | ﹤0.01% | 2528 |
|
|
2022
Q4 | $408K | Buy |
35,271
+8,456
| +32% | +$105K | ﹤0.01% | 2559 |
|
|
2022
Q3 | $400K | Buy |
26,815
+5,725
| +27% | +$78.5K | ﹤0.01% | 2504 |
|
|
2022
Q2 | $190K | Buy |
21,090
+913
| +5% | +$6.23K | ﹤0.01% | 3207 |
|
|
2022
Q1 | $151K | Sell |
20,177
-2,398
| -11% | -$16.7K | ﹤0.01% | 3412 |
|
|
2021
Q4 | $194K | Buy |
22,575
+1,202
| +6% | +$10.4K | ﹤0.01% | 3404 |
|
|
2021
Q3 | $180K | Sell |
21,373
-687
| -3% | -$5.26K | ﹤0.01% | 3620 |
|
|
2021
Q2 | $179K | Buy |
+22,060
| New | +$186K | ﹤0.01% | 3846 |
|
|
2020
Q1 | – | Sell |
-2,433
| Closed | -$7K | – | 4400 |
|
|
2019
Q4 | $7K | Buy |
2,433
+2,258
| +1,290% | +$9.22K | ﹤0.01% | 4577 |
|
|
2019
Q3 | $1K | Sell |
175
-7,170
| -98% | -$58.3K | ﹤0.01% | 4802 |
|
|
2019
Q2 | $75K | Sell |
7,345
-15,071
| -67% | -$201K | ﹤0.01% | 4340 |
|
|
2019
Q1 | $391K | Buy |
22,416
+6,502
| +41% | +$111K | ﹤0.01% | 3597 |
|
|
2018
Q4 | $279K | Buy |
15,914
+6,452
| +68% | +$191K | ﹤0.01% | 3687 |
|
|
2018
Q3 | $389K | Buy |
9,462
+7,364
| +351% | +$415K | ﹤0.01% | 3915 |
|
|
2018
Q2 | $120K | Buy |
+2,098
| New | +$101K | ﹤0.01% | 4481 |
|
Other funds holding COGT
JT
FFM
DM
TCM
Deutsche Bank's COGT Position: Q2 2026 in Review
Deutsche Bank increased its Cogent Biosciences (COGT) stake by 109% in Q2 2026, buying an estimated $4.87M and bringing the position to 266,584 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1049.
Deutsche Bank first reported a position in COGT in Q2 2018 and has held it in 28 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.
- Deutsche Bank held 266,584 shares of Cogent Biosciences worth $10.3M as of Q2 2026.
- Deutsche Bank bought 139,115 Cogent Biosciences shares in Q2 2026, an estimated $4.87M.
- Cogent Biosciences made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1049 holding.
- Deutsche Bank first reported a position in Cogent Biosciences in Q2 2018 and has held it in 28 quarters since.
- 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.
Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.